RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it has become the first company to earn National Committee for Quality Assurance (NCQA) certification in program design for a medication adherence program. NCQA accredits and certifies a wide range of healthcare organizations and manages the evolution of HEDIS(R), the performance measurement tool used by more than 90 percent of the nation’s health plans.
GSK’s unique new medication adherence program, ASK(SM) - Adherence Starts with Knowledge, uses a survey to identify a patient’s specific barriers to medication adherence. Based on the results, the healthcare providers can direct the patient to condition-specific resources that will help them understand their disease, set disease-specific healthcare goals and take charge of their health.
“Disease management offers tremendous promise for improving the care received by the chronically ill,” said NCQA President Margaret E. O’Kane. “By achieving NCQA Certification, an organization is showing that it is ready to provide specific services that can help fulfill that promise. It’s an accomplishment to be proud of.”
With certification, health plans have unbiased, third party confirmation from NCQA that GSK’s programs are evidence-based, well designed and appropriate for patients, practitioners and healthcare organizations. GSK does not directly provide disease management to patients but offers these materials to healthcare organizations for them to implement.
GSK’s medication adherence program was recognized by NCQA for its content and consistency with national disease-specific practice guidelines and met 100% of NCQA’s rigorous requirements.
“GlaxoSmithKline is committed to helping improve the quality of care for patients suffering from chronic conditions by developing evidence-based disease management and quality improvement programs,” said Tim Klapish, Executive Director, Medical Affairs Commercial Operations at GlaxoSmithKline. “NCQA certification validates our efforts and recognizes our dedication to quality and accountability.”
GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).
GlaxoSmithKline
CONTACT: Gaile Renegar, GlaxoSmithKline, +1-919-483-2319
Web site: http://www.gsk.com/
Company News On-Call: http://www.prnewswire.com/comp/801350.html/
